Radiation Therapy Safe for Myeloma Patients Before CAR T-cell Infusion, Study Finds
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…
Myeloma
New Nirogacestat Combos to Enter Myeloma Trials, SpringWorks Says
SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents…
Potential Cell Therapy for Multiple Myeloma Named Orphan Drug by FDA
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CellProtect, an investigational therapy for multiple myeloma…
No More Patients Needed in GENESIS Trial of Motixafortide, Committee Says
An independent data monitoring committee has recommended that the GENESIS Phase 3 trial evaluating motixafortide (formerly BL-8040), as a means to improve stem cell…
CLR 131 Elicits Promising Response Rates in Triple-refractory Multiple Myeloma Trial
CLR 131, Cellectar Biosciences’ lead experimental candidate, resulted in a 40% response rate among people with multiple myeloma who failed to respond…
‘Everybody Loves Raymond’ Cast Reunites for Virtual Fundraiser
The cast of the hit sitcom “Everybody Loves Raymond” reunited online to honor former co-star Peter Boyle for the International Myeloma Foundation’s (IMF)…
Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports
First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data…
Oncopeptides Will Seek Conditional Approval of Melflufen in Europe
Oncopeptides soon will seek conditional approval of melflufen (melphalan flufenamide) in the EU for the treatment of relapsed or refractory multiple myeloma. The pharmaceutical…
Sarclisa Triple Combo Conditionally Approved for NHS Use in England, Wales
After first rejecting a Sarclisa (isatuximab) triple combination therapy due to cost-effectiveness concerns, the U.K.’s National Institute for Health and Care…
1st Patient Dosed With Investigational T-cell Therapy NEXI-002 in Phase 1/2 Trial
NexImmune has dosed the first patient participating in its Phase 1/2 trial of NEXI-002, the company’s investigational T-cell therapy for multiple…
